ExodusPoint Capital Management LP raised its holdings in CareDx, Inc (NASDAQ:CDNA - Free Report) by 109.4% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 75,747 shares of the company's stock after buying an additional 39,566 shares during the period. ExodusPoint Capital Management LP owned approximately 0.14% of CareDx worth $1,622,000 as of its most recent SEC filing.
A number of other institutional investors also recently added to or reduced their stakes in the company. Trexquant Investment LP lifted its stake in CareDx by 60.1% in the fourth quarter. Trexquant Investment LP now owns 333,876 shares of the company's stock valued at $7,148,000 after buying an additional 125,363 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of CareDx by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 1,234,263 shares of the company's stock worth $26,432,000 after purchasing an additional 6,539 shares in the last quarter. Franklin Resources Inc. grew its stake in shares of CareDx by 91.4% during the 4th quarter. Franklin Resources Inc. now owns 113,859 shares of the company's stock worth $2,438,000 after purchasing an additional 54,385 shares during the period. Arrowstreet Capital Limited Partnership purchased a new position in shares of CareDx in the 4th quarter valued at about $731,000. Finally, Cornercap Investment Counsel Inc. acquired a new stake in shares of CareDx in the fourth quarter valued at about $214,000.
CareDx Trading Up 0.7 %
CDNA traded up $0.14 during trading hours on Monday, hitting $18.95. The company's stock had a trading volume of 70,596 shares, compared to its average volume of 855,461. CareDx, Inc has a fifty-two week low of $7.42 and a fifty-two week high of $34.84. The firm has a market capitalization of $1.05 billion, a PE ratio of -7.02 and a beta of 2.18. The company has a 50-day simple moving average of $20.23 and a 200 day simple moving average of $22.69.
CareDx (NASDAQ:CDNA - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported $1.51 earnings per share for the quarter, beating the consensus estimate of $0.05 by $1.46. The company had revenue of $86.58 million during the quarter, compared to analyst estimates of $84.56 million. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. Research analysts expect that CareDx, Inc will post -0.9 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of research analysts have issued reports on CDNA shares. StockNews.com upgraded shares of CareDx from a "hold" rating to a "buy" rating in a report on Wednesday, February 26th. Stephens reissued an "overweight" rating and set a $40.00 price target on shares of CareDx in a research note on Thursday, February 27th. HC Wainwright reduced their target price on CareDx from $26.00 to $25.00 and set a "neutral" rating on the stock in a research report on Monday, March 3rd. Finally, Wells Fargo & Company raised shares of CareDx from an "underweight" rating to an "equal weight" rating and dropped their price objective for the company from $28.00 to $24.00 in a research note on Wednesday, January 15th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $31.83.
Read Our Latest Analysis on CareDx
CareDx Company Profile
(
Free Report)
CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
See Also
Before you consider CareDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CareDx wasn't on the list.
While CareDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
